Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use IMJUDO safely and effectively. See full prescribing information for IMJUDO.IMJUDO® (tremelimumab-actl) injection, for intravenous useInitial U.S. Approval: 2022
Medication labelWhy this: Advisory · dailymed-prescription
IMJUDO, in combination with durvalumab, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). IMJUDO, in combination with durvalumab and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
- generic_name
- tremelimumab
- product_names
- tremelimumab
- ndc
- 0310-4505, 0310-4505-25, 0310-4535, 0310-4535-30
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en